Advisory Committee Unanimously Rejects Sanofi’s Zimulti
This article was originally published in The Pink Sheet Daily
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously votes against approval of Sanofi-Aventis’ rimonabant for a weight loss indication.
You may also be interested in...
GW Succeeding With Cannabinoid Drug This Time Around
Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.
Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.